| |
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
Today’s Big NewsJul 18, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Angus Liu As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included. |
|
|
|
By Darren Incorvaia Though his real name isn’t known, there’s no doubt that he’ll go down in history. An adult man dubbed “The Next Berlin Patient” has been declared the seventh person to be cured of HIV, and his case provides valuable information that could lead to a more broadly accessible cure for the 39 million people living with the virus around the globe. |
By Conor Hale The company’s earnings follow green lights for its first U.S. over-the-counter CGMs and dissolving stent for blocked arteries below the knee. |
By Nick Paul Taylor AstraZeneca has an unwanted hat trick of breaches of the U.K. pharma marketing code. The drugmaker completed the set after someone noticed the same compliance breach in two earlier cases, prompting the PCMPA to rule the company had brought discredit on the industry. |
|
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now. 
|
|
By Zoey Becker Through GoodRx, the German drugmaker's Humira copycat is priced 92% cheaper than AbbVie's branded Humira, which still holds 82% of the market despite the biosimilar competition. |
By James Waldron After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned. |
By Nick Paul Taylor PhRMA’s smarmy avatar for the alleged avarice of pharmacy benefit managers (PBMs) is back in a fresh attack ad. And this time there’s two of him, enabling the trade group to blast insurance companies and their PBMs at the same time. |
By Kevin Dunleavy After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo. |
By James Waldron The pharma has put “a lot of thought into” whether Novartis could play a role in the obesity space, Vas Narasimhan explained. |
By Fraiser Kansteiner Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade. |
By Nick Paul Taylor The FDA has scotched Agenus’ plans to seek accelerated approval for a colorectal cancer combination, prompting the biotech to look into partnering to fund the phase 3 required to reach the market. Shares in Agenus fell 38% to around $11 in premarket trading. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky and Fraiser Kansteiner discuss Fierce’s annual special report, “Big Pharma's 10 highest-paid CEOs.” |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now. 
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
